Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SUTENT (SUNITINIB, SU11248) in Patients With Recurrent or Progressive Glioblastoma Multiforme An Academic Prospective Single-Arm Phase II Clinical Trial Including Translational Research Studies.

Trial Profile

SUTENT (SUNITINIB, SU11248) in Patients With Recurrent or Progressive Glioblastoma Multiforme An Academic Prospective Single-Arm Phase II Clinical Trial Including Translational Research Studies.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Jan 2014

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 27 Aug 2010 Planned end date changed from 1 Jun 2010 to 1 Jan 2011 as reported by ClinicalTrials.gov.
    • 03 Feb 2009 Additional lead investigator identified as reported by ClinicalTrials.gov, last updated 3-2-2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top